Inhalation Sciences ramps up popular expert webinar series with new release on May 2[nd], 2023
(Stockholm, Sweden, 19 April 2023) Following its highly successful webinar on DissolvIt dissolution studies on March 30th – 300 people registered – Inhalation Sciences AB (ISAB) will release two new webinars in 2023. Each will be partnered and co-presented by an industry expert. The next, on May 2nd 2023, features in vivo exposures for inhaled medicines with ISAB’s PreciseInhale aerosol system showcased by Per Gerde, ISAB’s CSO and Founder, and inhalation expert Matt Reed from Coelus Bio. Register for the seminar below.
ISAB is partnering with industry experts in two new webinars in its popular series. The latest webinar, on its unique in vitro module, the DissolvIt method, was extremely well-received, attracting 300 subscribers. It was co-presented by bioanalytic consultant Prof Hermann Mascher, together with ISAB’s in vitro specialist and Director of Projects Dr. Maria Malmlöf. Watch the webinar HERE.
Webinar #2: May 2nd 2023
ISAB will present its next webinar, on in vivo studies, on May 2nd 2023 . It will be co-presented by an expert in the field - Matt Reed from Coelus Bio. Matt is a pharmacologist and a board-certified toxicologist with over 25 years’ experience in which he has been a part of multiple successful R&D programs that that have transitioned to regulatory approval for small molecules, biologics, oligonucleotides
Register for the May 2nd webinar HERE
ISAB offers a competitive range of in vivo testing solutions, including its unique intratracheal module. The module uses a catheter connected to PreciseInhale that bypasses the nasal airways, ensuring test substances are retained in the lung and delivering high-precision data of, typically, <10% Standard Deviation.
Webinar #3 – customer partner
ISAB’s third expert webinar is expected to be presented later in Fall 2023.
CEO Manoush Masarrat: “These webinars are a superb showcase of our unique expertise and capabilities. I would urge anyone in inhaled pharmaceutical development who is interested in de-risking their drug development early on to register and take part. Our inhalation research services (IRS) are an important key to growth for us, as we share our knowledge and capabilities we build partnerships, increase sales and accelerate our sales cycles.”
